Home/Filings/4/0001104659-22-024841
4//SEC Filing

Kalkofen Donald A. 4

Accession 0001104659-22-024841

CIK 0001377121other

Filed

Feb 16, 7:00 PM ET

Accepted

Feb 17, 7:26 PM ET

Size

7.4 KB

Accession

0001104659-22-024841

Insider Transaction Report

Form 4
Period: 2022-02-15
Kalkofen Donald A.
Chief Financial Officer
Transactions
  • Award

    Common Stock

    2022-02-15+7,50018,521 total
  • Award

    Stock Option (right to buy)

    2022-02-15+45,00045,000 total
    Exercise: $28.73Exp: 2032-02-14Common Stock (45,000 underlying)
Footnotes (3)
  • [F1]Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on February 15, 2023, 2024 and 2025.
  • [F2]Includes an aggregate of 635 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2021.
  • [F3]The stock option vests in 48 equal monthly installments following the date of grant.

Issuer

Protagonist Therapeutics, Inc

CIK 0001377121

Entity typeother

Related Parties

1
  • filerCIK 0001771066

Filing Metadata

Form type
4
Filed
Feb 16, 7:00 PM ET
Accepted
Feb 17, 7:26 PM ET
Size
7.4 KB